

## SUPPLEMENT 2: Success States Questionnaire

### Addressing Lupus Pillars for Health Advancement (ALPHA) Project Questionnaire for Global Advisory Committee (GAC) Members

During the January 2020 GAC meeting, we will be identifying potential global solutions to the barriers identified in Phase One of the ALPHA project across three pillars: drug development, clinical care, and access to care. This brief survey is intended to help frame what constitutes success from GAC members' perspectives.

For this exercise, we ask you to provide a brief, specific description of the future state you hope we can achieve for each pillar. Please note that this questionnaire is intended to determine the "what" rather than the "how" of success for each pillar – we will be brainstorming specific solutions and pathways during the meeting in January. As an example in general drug development, a "what" (high level conceptual) target would be: reducing regulatory agency review time for new drug applications and a "how" (more process-/implementation-oriented) target would be: requiring regulatory agencies to report on amount of review time spent on preclinical vs. clinical data review.

Please send your responses by **Monday, December 9** to Karin (tse@lupus.org). Thank you.

Your Name: \_\_\_\_\_

<b>1. How would you define success for lupus drug development?</b>	
Barriers identified in ALPHA Phase I: <ul style="list-style-type: none"> <li>• Lack of biomarkers to predict drug response</li> <li>• Limitations of current outcome measures</li> <li>• Flawed trial design</li> </ul>	
<b>2. How would you define success for lupus clinical care?</b>	
Barriers identified in ALPHA Phase I: <ul style="list-style-type: none"> <li>• Lack of diagnostic, predictive, and prognostic biomarkers</li> <li>• Lack of treatment adherence</li> </ul>	
<b>3. How would you define success for access to care for lupus?</b>	
Barriers identified in ALPHA Phase I: <ul style="list-style-type: none"> <li>• Social determinants of care in low socioeconomic areas</li> <li>• Lack of access to clinicians</li> </ul>	